The US "medical insurance price negotiations" hindered, and pharmaceutical companies desperately lobby officials and refused to reduce prices

The "soul bargaining" is released from new regulations, and pharmaceutical companies actively cut prices to hung the net ... In China, the atmosphere of the state talk in 2022 was just right; but at the other end of the ocean, the American version of "medical insurance price negotiations" was blocked.

Since 2021, the US Biden government has begun to accelerate the implementation of the new policy, trying to reduce the price of some drugs in the Medicare directory in the US version of the medical insurance through "price negotiation". On July 25, Fiere Pharma reported that the United States Metallador Association (NAM) is the largest industrial and trade industry organization in the United States.

They took out a 6 -digit budget to advertise and linked the negotiations with the concept of innovation, and believed that the price and control price would "prevent life -saving medicines from entering the market."

NAM is the organization of the platform of US pharmaceutical companies. According to the analysis of investment institutions ODDO BHF, the "price negotiations" in the United States mainly affect large pharmaceutical vendors such as Asley, Novartis, Roche, and Sanofi. More than 10%of these companies are paid by the "American Medical Insurance Fund".

It is reported that in the first half of 2021, these pharmaceutical companies spent nearly $ 200 million in "lobbying members".

Started in 2023, the US market is not easy to do

In July 2021, US President Biden signed an administrative order to "crack down on the price of US prescription drugs too high" by means of promoting the competition of generic drug competition and giving the MEDICARE price negotiation qualification.

In November of that year, the House of Representatives of the United States officially passed the "Build Back Better Act" bill, and gave the MEDICARE drug price negotiation right. The U.S. government said that if companies refuse to negotiate, the United States will levy 95%of the consumption tax on the profits of related drugs.

This is much more severe than China's medical insurance negotiation rules, and the negotiations are targeted at mature varieties that have been listed. Specifically, since 2023, Medicare has selected 10 drugs and pharmaceutical companies each year. The selected drugs are required to be exclusive varieties with more than 9 years of listing.

The overall drug in the United States is much more expensive than China. In early June, several researchers from Harvard University School of Medicine jointly released a research report on "2008-2021 Prescription Pharmaceutical Price Trends". The study stated that in the past 13 years, the median number of drug prices rose from US $ 2115 to $ 180,000. New drugs The average annual increase of listed prices increased by 20.4%. Some institutions have also calculated that the price of the original US -developed drugs was about 3.44 times that of other OECD countries.

In order to maintain high returns, pharmaceutical companies have continued to find ways to extend the protection period of the original research products. Taking Albervi's "Medicine King" as an example, in 2018, the biological medicines of Adamumab were already listed in Europe, and similar medicines approved by China were about 10 kinds of similar medicines. However, in the United States, because Albervi applied for more than 200 patents, Ada Mutam's anti -anti -similar drugs could only be listed in 2023.

This is why many domestic innovative pharmaceutical companies want to go to sea. However, even if domestic companies are approved by the FDA, they will encounter blocking from major pharmaceutical companies in the United States.

Moreover, the US "medical insurance system" has a stronger bargaining ability. When Chinese companies really go to sea, the US version of the price negotiations will be fully struck.

This is the current US market policy risk that domestic pharmaceutical companies have to consider.

Chinese and foreign pharmaceutical companies are the same: price reduction affects R & D investment

Medicare is currently the most widely covered by audiences in the United States. The expenditure of retail drugs accounted for 1/3 of the total drug of this type of drug. If Medicare has the ability to "price negotiation", it may help solve the problem of high US drug prices Essence

Previously, US law stipulated that the federal government could not restrict drug prices and interfere with the market in the form of price negotiations. When Biden came to power, he promised to suppress the price of medicine, which was the "medical insurance price negotiation" in the United States today.

On behalf of pharmaceutical companies, NAM complains: economic pressure is already large enough, and the state should focus on "enhance the competitiveness of the industry", rather than "forced drug reduction". Some people also argued that after the industry calculated that every 10%of the drug prices decreased, the research and development funding invested by enterprises would be reduced by 17%accordingly, which will eventually lead to the delay of drugs or not being available.

This series of rhetoric is exactly the same as the current Chinese pharmaceutical industry.

In this regard, the US Congress Budget Office stated that although price negotiations will "prevent about 10 drugs from being listed" in the next 30 years, in the next 30 years, there will be more than 1,000 potential new drugs. Moreover, in less than 10 years, price negotiations can save about $ 288 billion in budget for the federal government. There is really no reason not to execute.

The price of drugs in the United States is high, and there are also issues similar to China's "multi -vote system". In the United States, between the three parties of insurance companies, pharmaceutical companies, pharmacies and pharmacies, there is also an intermediary role of "pharmacy manager". Insurance companies often collectively "place orders", entrusted pharmacy managers to talk about payments with pharmaceutical companies. However, this intermediate link of the pharmacy manager began to seek discounts and returns from all parties.

According to data, nearly 30 % of the total sales of US $ 425 billion in prescription drugs in the United States fell into the middle link in 2015.

The United States did not implement the "two -vote system". In 2021, Sanofi was sued by a number of distributors to court, saying that Senfei was suspected of raising insulin prices through pharmacy managers.

The price of drug prices in the United States is actually very similar to China. Therefore, government departments have also adopted similar methods to China. The above three Harvard scholars' views believe that the United States should ban the "free pricing of pharmaceutical companies" and implement the strategy of multi -party negotiation and pricing. It is said that Biden's "medical insurance price negotiation" policy has received more than 80%of the US public support.

refer to:

NAM RUNS 6-Figure Ad Campaign Lambasting Drug Price Controls (Fierecepharma.com);

Novo Nordisk, Roche See Outsized Threats from U.S. Drug Pricing Talks: Analysts | Fiere Pharma;

President Biden Annotes Prescription Drug Price Plan in Build Better Framework | The White House;

With d.c. Drug Pricing Talks up in the Air, The 'Endgame' Could Still 'Have a Bite,' Analyst Says | Fiere Pharm;

Harvard, Kesselheim Paper Highlights Almost 90X Increase in Launch Prices for New Drugs Since 2008 - Endpoints News (EndPTS.com)

Writing ｜ Guyue

Edit ｜ Jiang Yun Jia Ting

Operation ｜ Valley

Photo Source ｜ Visual China

### American Medicine Price ## Pharmaceutical Company#

- END -